JPMorgan reiterates Overweight rating
- Mylan raised its 3Q and full-year EPS range this morning, which follows yesterday's news reports that Teva had approached Mylan about a potential merger.
- Firm sees rationale behind a potential merger given the opportunity for meaningful cost synergies, commercial overlap and increased scale between the two businesses.